Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zemlikafusp Alfa · IPH6501

Bispecific antibody (Multispecific) · Immune activation, directed at NKp46 (NCR1), CD16a (FcgammaRIIIa) (FCGR3A) and CD20 (MS4A1) · developed by Innate Pharma

Phase 1/2 Most advanced trial (none active)
IPHA Developer
1 Registered trials

What is Zemlikafusp Alfa?

Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager built from antibody fragments against NKp46 and CD16a on natural killer cells and CD20 on tumor cells, plus a non-alpha interleukin-2 variant that binds the IL-2 receptor beta chain (CD122). It bridges NK cells to CD20-expressing cancer cells to stimulate NK cell activation and cytotoxicity. It is being studied in non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPH6501
Drug type
Bispecific antibody (Multispecific)
Targets
NKp46 (NCR1), CD16a (FcgammaRIIIa) (FCGR3A), CD20 (MS4A1), IL-2 receptor beta chain (CD122) (IL2RB)
Mechanism
Immune activation, directed at NKp46 (NCR1), CD16a (FcgammaRIIIa) (FCGR3A) and CD20 (MS4A1)
Pathways
NK cell proliferation and activation, NK cell-mediated cytokine secretion and cytotoxicity
Therapy area
Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
EQ9AQ9UV4F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06088654 Phase 1/2 Non Hodgkin Lymphoma Terminated IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Hodgkin Lymphoma

Other drugs acting on NCR1 / FCGR3A / MS4A1 / IL2RB

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind Zemlikafusp Alfa

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.